Cell Death Discovery · 2024 · 19 citations · 15 references
MedicineImmunologyOncologyCancer ImmunologyMolecular OncologyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyImmune Evasion In CancerAdaptive Antitumor ImmunityNon-small Cell Lung Cancer ImmunotherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentOncogenic Immune Evasion PathwaysProgrammed Cell Death Protein 1 (Pd-1) Pathway
Abstract Immune evasion is one of the critical hallmarks of malignant tumors, especially non-small cell lung cancer (NSCLC). Emerging findings have illustrated the roles of N 6 -methyladenosine (m 6 A) on NSCLC immune evasion. Here, this study investigated the function and underlying mechanism of m 6 A reader YTH domain family protein 3 (YTHDF3) on NSCLC immune evasion. YTHDF3 was found to be highly expressed in NSCLC tissue and act as an independent prognostic factor for overall survival. Functionally, up-regulation of YTHDF3 impaired the CD8 + T antitumor activity to deteriorate NSCLC immune evasion, while YTHDF3 silencing recovered the CD8 + T antitumor activity to inhibit immune evasion. Besides, YTHDF3 up-regulation reduced the apoptosis of NSCLC cells. Mechanistically, PD-L1 acted as the downstream target for YTHDF3, and YTHDF3 could upregulate the transcription stability of PD-L1 mRNA. Overall, YTHDF3 targeted PD-L1 to promote NSCLC immune evasion partially through escaping effector cell cytotoxicity CD8 + T mediated killing and antitumor immunity. In summary, this study provides an essential insight for m 6 A modification on CD8 + T cell-mediated antitumor immunity in NSCLC, which might inspire an innovation for lung cancer tumor immunotherapy.
15
First-Line Immunotherapy for Non–Small-Cell Lung Cancer
Journal of Clinical Oncology · 2022 · 843 citations
Medicine, Immunology, Oncology +17
Zhenchuan Liu, Tingting Wang, Yunlang She et al. · Molecular Cancer · 2021 · 506 citations · Full text
Medicine, Immunology, Oncology +17